Cargando…
A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders
It is required that the clinical screening of metabolic disorders in newborns meet International Organization for Standardization 15189-2012 approval. The new tandem mass spectrometry (MS/MS) based screening system and its companion reagent should be independently authenticated before their implemen...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531236/ https://www.ncbi.nlm.nih.gov/pubmed/31083189 http://dx.doi.org/10.1097/MD.0000000000015500 |
_version_ | 1783420792635129856 |
---|---|
author | Zheng, Yulan Chen, Yao Qiu, Xiaolong Chen, Weifen Lin, Qingying Zeng, Yinglin Zhao, Hong Zhu, Wenbin |
author_facet | Zheng, Yulan Chen, Yao Qiu, Xiaolong Chen, Weifen Lin, Qingying Zeng, Yinglin Zhao, Hong Zhu, Wenbin |
author_sort | Zheng, Yulan |
collection | PubMed |
description | It is required that the clinical screening of metabolic disorders in newborns meet International Organization for Standardization 15189-2012 approval. The new tandem mass spectrometry (MS/MS) based screening system and its companion reagent should be independently authenticated before their implementation in clinical diagnosis laboratories. Linearity, stability, accuracy, and precision evaluations were carried out to verify the performance of the Waters ACQUITY TQD MS/MS system with the NeoBase non-derivatized MS/MS PerkinElmer kit for detecting amino acids and acylcarnitine in newborns with metabolic disorders. Statistically, the correlation coefficient (R(2)) of 0.9982 to 0.9999 indicates good linearity. The measurements at the beginning and end of the reagent storage procedure were taken for stability verification. No significant difference was detected between the 2 periods. The amino acid exhibited a degree of bias in the range of 0% to 14.17%, with acylcarnitine's being was in the range of 0% to 14.84%; they consequently passed the quality assessment requirements for clinical laboratories of the China National Centre. The amino acids’ within-run, between-run, and day-to-day run precision were 1.19% to 7.68%, 1.63% to 5.01%, and 4.77% to 12.48%, respectively, while the total imprecision was 5.55% to 13.33%. Acylcarnitine's within-run, between-run, and day-to-day run precision was 1.2% to 8.43%, 0.19% to 9.60%, and 2.33% to 10.74%, respectively, while it's total imprecision was 6.57% to 13.99%. The manufacturer declared that the total imprecision of the tests, using Multiple Reaction Monitoring, should be less than or equal to 25% of the coefficient of variation for the kit's high and low-quality control levels. The performance of the non-derivatized MS/MS screening system in detecting the amino acids and acylcarnitines passed the test's requirements. It was maintained in accordance with the routine clinical chemical detection system. |
format | Online Article Text |
id | pubmed-6531236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-65312362019-06-25 A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders Zheng, Yulan Chen, Yao Qiu, Xiaolong Chen, Weifen Lin, Qingying Zeng, Yinglin Zhao, Hong Zhu, Wenbin Medicine (Baltimore) Research Article It is required that the clinical screening of metabolic disorders in newborns meet International Organization for Standardization 15189-2012 approval. The new tandem mass spectrometry (MS/MS) based screening system and its companion reagent should be independently authenticated before their implementation in clinical diagnosis laboratories. Linearity, stability, accuracy, and precision evaluations were carried out to verify the performance of the Waters ACQUITY TQD MS/MS system with the NeoBase non-derivatized MS/MS PerkinElmer kit for detecting amino acids and acylcarnitine in newborns with metabolic disorders. Statistically, the correlation coefficient (R(2)) of 0.9982 to 0.9999 indicates good linearity. The measurements at the beginning and end of the reagent storage procedure were taken for stability verification. No significant difference was detected between the 2 periods. The amino acid exhibited a degree of bias in the range of 0% to 14.17%, with acylcarnitine's being was in the range of 0% to 14.84%; they consequently passed the quality assessment requirements for clinical laboratories of the China National Centre. The amino acids’ within-run, between-run, and day-to-day run precision were 1.19% to 7.68%, 1.63% to 5.01%, and 4.77% to 12.48%, respectively, while the total imprecision was 5.55% to 13.33%. Acylcarnitine's within-run, between-run, and day-to-day run precision was 1.2% to 8.43%, 0.19% to 9.60%, and 2.33% to 10.74%, respectively, while it's total imprecision was 6.57% to 13.99%. The manufacturer declared that the total imprecision of the tests, using Multiple Reaction Monitoring, should be less than or equal to 25% of the coefficient of variation for the kit's high and low-quality control levels. The performance of the non-derivatized MS/MS screening system in detecting the amino acids and acylcarnitines passed the test's requirements. It was maintained in accordance with the routine clinical chemical detection system. Wolters Kluwer Health 2019-05-13 /pmc/articles/PMC6531236/ /pubmed/31083189 http://dx.doi.org/10.1097/MD.0000000000015500 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Zheng, Yulan Chen, Yao Qiu, Xiaolong Chen, Weifen Lin, Qingying Zeng, Yinglin Zhao, Hong Zhu, Wenbin A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders |
title | A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders |
title_full | A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders |
title_fullStr | A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders |
title_full_unstemmed | A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders |
title_short | A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders |
title_sort | verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531236/ https://www.ncbi.nlm.nih.gov/pubmed/31083189 http://dx.doi.org/10.1097/MD.0000000000015500 |
work_keys_str_mv | AT zhengyulan averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT chenyao averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT qiuxiaolong averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT chenweifen averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT linqingying averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT zengyinglin averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT zhaohong averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT zhuwenbin averificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT zhengyulan verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT chenyao verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT qiuxiaolong verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT chenweifen verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT linqingying verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT zengyinglin verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT zhaohong verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders AT zhuwenbin verificationoftheapplicationofthenonderivatizedmassspectrometrymethodinnewbornsscreeningofmetabolicdisorders |